Eikon Therapeutics, Inc. Common Stock
EIKN
Rank in Stocks
#14875
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established... Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Share Price
$5.15
Last synced: 2026-11-17
Market Cap
$278.97M
Change (1 day)
-4.45%
Change (1 year)
-
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Eikon Therapeutics, Inc. Common Stock (EIKN)
Category
Healthcare
EPS for Eikon Therapeutics, Inc. Common Stock (EIKN)
EPS as of September 2026 TTM: $-6.22
According to Eikon Therapeutics, Inc. Common Stock's latest financial reports, its current EPS (TTM) is $-6.22. At the end of 2026 the company had an EPS of 0, equal to its 2026 EPS of 0.
EPS history for Eikon Therapeutics, Inc. Common Stock from 2025 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-6.22 | 0.97% |
| 2025 | $-6.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -351.77% |
US
|
|
| $-7.07 | 13.67% |
US
|
|
| $-5.29 | -14.95% |
AU
|
|
| $12.73 | -304.70% |
BE
|
|
| $21.56 | -446.62% |
NL
|
Questions about Eikon Therapeutics, Inc. Common Stock's earnings per share (EPS)
What is Eikon Therapeutics, Inc. Common Stock's earnings per share (EPS)?
Eikon Therapeutics, Inc. Common Stock's earnings per share (EPS) over the last twelve months is $-6.22, as of Sep 2026.
How does Eikon Therapeutics, Inc. Common Stock's earnings per share (EPS) compare with similar companies?
Eikon Therapeutics, Inc. Common Stock's earnings per share (EPS) ($-6.22) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.